Theodore Leng, MD
Ophthalmology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 25
- 6 carriers
- Offices
- 8
Offices
8 locations · Stanford Health Care · University Healthcare Alliance · County of Santa Clara
Hospitals listed: Santa Clara Valley Medical Center · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
25 plans · 6 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Leng’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
25 of 25 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A106892 · Current
Licensed to practise in California · since 2009 · expires 2027-03-31 · Stanford University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$316,891
Medicare paid this office $316,891 for 1,168 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 962 | $123,187 | $80 |
| Injection of drug into eye | 201 | $104,920 | $92 |
| Imaging of retina | 926 | $46,315 | $21 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 556 | $10,012 | $15 |
| New patient visit (45+ min) | 72 | $6,207 | $86 |
See all 10 services
| Return visit (30+ min) | 962 | $123,187 | $80 |
| Injection of drug into eye | 201 | $104,920 | $92 |
| Imaging of retina | 926 | $46,315 | $21 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 556 | $10,012 | $15 |
| New patient visit (45+ min) | 72 | $6,207 | $86 |
| Imaging of retina with remote review by physician | 78 | $1,003 | $13 |
| Imaging of retina with remote review by physician | 43 | $595 | $14 |
| Photography of the retina | 25 | $419 | $16 |
| Measurement of corneal curvature and depth of eye | 14 | $367 | $24 |
| Exam of visual field with extended testing | 14 | $299 | $21 |
Procedures Medicare counted
| Cataract surgery | 11 | More than 32% of doctors who do this |
Who their Medicare patients are
1,168 Original Medicare patients in 2024. Average age 76 · Under 65 5% · 85 and older 19% · Women 52% · Also on Medicaid 20% · Health risk score 1.37. Above the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 70% · Diabetes 46% · Coronary heart disease 26% · Chronic kidney disease 26% · Cancer 19% · Heart failure 15% · Atrial fibrillation 15% · Depression 14% · COPD 8% · Stroke 8% · Dementia 6%.
The office billed $2,583,038, Medicare allowed $432,359 and paid $316,891; for 5,898 services of 31 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,168 | 5,898 | 76 | 1.37 | $2,583,038 | $316,891 |
| 2023 | 1,068 | 4,975 | 77 | 1.47 | $2,019,972 | $303,686 |
| 2022 | 1,068 | 4,772 | 76 | 1.36 | $1,693,573 | $274,924 |
| 2021 | 1,051 | 4,746 | 76 | 1.40 | $1,696,589 | $292,954 |
| 2020 | 862 | 4,129 | 76 | 1.44 | $1,463,388 | $235,681 |
| 2019 | 906 | 4,888 | 75 | 1.50 | $1,824,365 | $295,908 |
| 2018 | 860 | 4,823 | 76 | 1.52 | $1,777,077 | $284,219 |
| 2017 | 863 | 4,684 | 76 | 1.53 | $1,930,354 | $285,357 |
| 2016 | 855 | 4,897 | 75 | 1.47 | $1,888,040 | $311,233 |
| 2015 | 804 | 6,078 | 76 | 1.48 | $3,376,658 | $1,006,747 |
| 2014 | 827 | 6,059 | 75 | 1.29 | $3,255,741 | $1,047,735 |
| 2013 | 772 | 5,612 | 75 | 1.43 | $2,864,397 | $826,816 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| Return visit (30+ min) | 874 | $115,041 | $83 |
| Injection of drug into eye | 206 | $113,260 | $96 |
| Imaging of retina | 870 | $47,004 | $23 |
| New patient visit (45+ min) | 92 | $9,688 | $105 |
| Imaging of retina with remote review by physician | 48 | $632 | $13 |
| Short return visit (20+ min) | 11 | $571 | $48 |
| Photography of the retina | 20 | $452 | $18 |
| Imaging of retina with remote review by physician | 27 | $417 | $15 |
| Measurement of corneal curvature and depth of eye | 13 | $400 | $29 |
| Imaging of retina | 15 | $350 | $18 |
2022: 10 services
| Injection of drug into eye | 194 | $102,139 | $88 |
| Return visit (30+ min) | 826 | $98,002 | $78 |
| Imaging of retina | 804 | $43,628 | $22 |
| New patient visit (45+ min) | 79 | $8,307 | $105 |
| Imaging of retina with remote review by physician | 61 | $880 | $14 |
| Imaging of retina with remote review by physician | 55 | $859 | $16 |
| Short return visit (20+ min) | 12 | $658 | $51 |
| Photography of the retina | 23 | $431 | $17 |
| Exam of visual field with extended testing | 14 | $353 | $24 |
| Imaging of retina | 12 | $332 | $21 |
2021: 13 services
| Injection of drug into eye | 188 | $104,855 | $92 |
| Return visit (30+ min) | 735 | $89,726 | $84 |
| Imaging of retina | 800 | $44,635 | $22 |
| New patient visit (45+ min) | 99 | $11,384 | $115 |
| Established patient complete exam of visual system | 131 | $4,352 | $33 |
| Imaging of retina with remote review by physician | 70 | $1,251 | $17 |
| Short return visit (20+ min) | 16 | $816 | $48 |
| New patient complete exam of visual system | 12 | $814 | $68 |
| Imaging of retina with remote review by physician | 33 | $575 | $17 |
| Photography of the retina | 14 | $385 | $20 |
| Measurement of corneal curvature and depth of eye | 14 | $297 | $21 |
| Imaging of retina | 14 | $295 | $20 |
| Imaging of retina with remote review by clinical staff | 12 | $80 | $7 |
2020: 14 services
| Injection of drug into eye | 174 | $108,223 | $98 |
| Return visit (30+ min) | 557 | $52,914 | $64 |
| Imaging of retina | 632 | $37,930 | $22 |
| New patient visit (45+ min) | 46 | $5,017 | $109 |
| Short return visit (20+ min) | 77 | $2,905 | $36 |
| Long return visit (40+ min) | 21 | $2,053 | $98 |
| Injection of drug into eye | 18 | $1,646 | $82 |
| Imaging of retina with remote review by clinical staff | 109 | $1,403 | $13 |
| Return visit (30+ min) | 24 | $1,358 | $57 |
| Imaging of retina | 38 | $820 | $21 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 15 | $632 | $40 |
| New patient visit (30+ min) | 11 | $601 | $55 |
| Measurement of corneal curvature and depth of eye | 11 | $303 | $28 |
| Photography of the retina | 16 | $250 | $16 |
2019: 12 services
| Injection of drug into eye | 192 | $122,699 | $99 |
| Return visit (30+ min) | 642 | $69,910 | $66 |
| Imaging of retina | 749 | $47,562 | $23 |
| Removal of cataract with insertion of prosthetic lens | 11 | $9,955 | $622 |
| New patient visit (45+ min) | 50 | $5,551 | $111 |
| Long return visit (40+ min) | 53 | $5,140 | $95 |
| Short return visit (20+ min) | 108 | $4,227 | $34 |
| Established patient problem focused exam of visual system | 25 | $1,292 | $40 |
| Injection of drug into eye | 11 | $950 | $63 |
| Photography of the retina | 40 | $890 | $19 |
| Imaging of retina | 23 | $666 | $21 |
| Measurement of corneal curvature and depth of eye | 15 | $451 | $30 |
2018: 10 services
| Injection of drug into eye | 187 | $121,058 | $97 |
| Return visit (30+ min) | 601 | $66,573 | $64 |
| Imaging of retina | 722 | $46,241 | $22 |
| Short return visit (20+ min) | 151 | $7,368 | $40 |
| New patient visit (45+ min) | 53 | $5,632 | $106 |
| Long return visit (40+ min) | 21 | $1,989 | $95 |
| Imaging of retina | 32 | $860 | $23 |
| Return visit (30+ min) | 13 | $848 | $65 |
| Short return visit (20+ min) | 13 | $597 | $43 |
| Photography of the retina | 25 | $448 | $18 |
2017: 13 services
| Injection of drug into eye | 188 | $111,113 | $97 |
| Return visit (30+ min) | 612 | $66,694 | $63 |
| Imaging of retina | 737 | $44,439 | $22 |
| Removal of membrane of retina with removal of internal limiting membrane of retina | 14 | $16,148 | $1,077 |
| Removal of cataract with insertion of prosthetic lens | 14 | $10,366 | $576 |
| New patient visit (45+ min) | 73 | $6,870 | $94 |
| Short return visit (20+ min) | 108 | $5,218 | $39 |
| Long return visit (40+ min) | 50 | $4,780 | $96 |
| Injection of drug into eye | 12 | $1,325 | $70 |
| New patient visit (30+ min) | 14 | $902 | $64 |
| Measurement of corneal curvature and depth of eye | 18 | $502 | $28 |
| Photography of the retina | 26 | $427 | $16 |
| Examination of eye by ophthalmoscope with retinal drawing | 11 | $201 | $18 |
2016: 17 services
| Injection of drug into eye | 205 | $105,293 | $95 |
| Imaging of retina | 739 | $50,092 | $25 |
| Return visit (30+ min) | 353 | $37,606 | $63 |
| Established patient complete exam of visual system | 414 | $35,296 | $67 |
| Removal of membrane of retina with removal of internal limiting membrane of retina | 21 | $22,423 | $1,068 |
| New patient visit (45+ min) | 122 | $12,787 | $105 |
| Long return visit (40+ min) | 70 | $6,678 | $95 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 55 | $5,114 | $43 |
| Exam of blood vessels between the white part of eye and retina using a special camera after injection of a dye | 33 | $4,323 | $58 |
| Short return visit (20+ min) | 26 | $1,486 | $42 |
| 2d ultrasound scan of eye tissue and structures | 18 | $1,191 | $46 |
| New patient visit (30+ min) | 12 | $662 | $55 |
| Photography of the retina | 21 | $420 | $20 |
| Exam of visual field with extended testing | 14 | $390 | $26 |
| Measurement of corneal curvature and depth of eye | 12 | $349 | $29 |
| Imaging of optic nerve | 12 | $271 | $21 |
| Examination of eye by ophthalmoscope with retinal drawing | 14 | $256 | $18 |
2015: 19 services
| Injection, aflibercept, 1 mg | 67 | $581,201 | None |
| Injection of drug into eye | 155 | $65,801 | $89 |
| Injection of drug into eye | 102 | $54,987 | $110 |
| Return visit (30+ min) | 438 | $47,708 | $65 |
| Imaging of retina | 570 | $35,837 | $26 |
| Imaging of retina | 176 | $26,979 | $45 |
| Return visit (30+ min) | 158 | $23,489 | $90 |
| Removal of membrane of retina with removal of internal limiting membrane of retina | 19 | $19,438 | $1,023 |
| New patient visit (45+ min) | 100 | $10,702 | $107 |
| Exam of blood vessels between the white part of eye and retina using a special camera after injection of a dye | 28 | $10,319 | $265 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 76 | $7,023 | $43 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 44 | $6,951 | $105 |
| Unclassified biologics | 34 | $6,623 | None |
| Exam of blood vessels between the white part of eye and retina using a special camera after injection of a dye | 44 | $5,696 | $59 |
| Established patient complete exam of visual system | 84 | $5,677 | $62 |
| 2d ultrasound scan of eye tissue and structures | 22 | $1,193 | $50 |
| Short return visit (20+ min) | 13 | $990 | $71 |
| Short return visit (20+ min) | 18 | $955 | $45 |
| Photography of the retina | 32 | $691 | $21 |
2014: 23 services
| Injection, aflibercept, 1 mg | 54 | $590,398 | None |
| Injection, ranibizumab, 0.1 mg | 16 | $114,544 | None |
| Injection of drug into eye | 90 | $64,602 | $106 |
| Injection of drug into eye | 124 | $56,966 | $89 |
| Return visit (30+ min) | 384 | $38,405 | $64 |
| Imaging of retina | 564 | $32,054 | $25 |
| Imaging of retina | 176 | $30,877 | $43 |
| Return visit (30+ min) | 144 | $20,486 | $89 |
| Removal of membrane of retina with removal of internal limiting membrane of retina | 12 | $18,623 | $1,433 |
| Unclassified biologics | 36 | $9,430 | None |
| New patient visit (45+ min) | 82 | $8,249 | $101 |
| Established patient complete exam of visual system | 104 | $7,007 | $64 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 38 | $3,629 | $44 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 26 | $3,038 | $108 |
| Established patient complete exam of visual system | 14 | $1,565 | $98 |
| New patient complete exam of visual system | 22 | $1,322 | $60 |
| 2d ultrasound scan of eye tissue and structures | 13 | $965 | $48 |
| Short return visit (20+ min) | 20 | $925 | $44 |
| Photography of the retina | 28 | $710 | $20 |
| Examination of eye by ophthalmoscope with retinal drawing | 30 | $587 | $20 |
| Examination of eye by ophthalmoscope with retinal drawing | 23 | $517 | $17 |
| Examination of eye by ophthalmoscope with retinal drawing | 20 | $497 | $24 |
| Examination of eye by ophthalmoscope with retinal drawing | 11 | $268 | $24 |
2013: 25 services
| Injection, aflibercept, 1 mg | 37 | $350,137 | None |
| Injection, ranibizumab, 0.1 mg | 13 | $104,736 | None |
| Injection of drug into eye | 139 | $51,196 | $88 |
| Return visit (30+ min) | 370 | $46,776 | $64 |
| Injection of drug into eye | 70 | $40,542 | $99 |
| Removal of membrane of retina with removal of internal limiting membrane of retina | 28 | $39,444 | $1,409 |
| Imaging of retina | 515 | $29,172 | $25 |
| Return visit (30+ min) | 120 | $26,771 | $90 |
| Imaging of retina | 145 | $22,015 | $43 |
| Complex repair of detached retina and drainage of eye fluid between lens and retina | 13 | $20,859 | $1,605 |
| New patient visit (45+ min) | 93 | $9,748 | $105 |
| Short return visit (20+ min) | 140 | $7,700 | $42 |
| Unclassified biologics | 27 | $5,293 | None |
| Short return visit (20+ min) | 50 | $4,883 | $64 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 31 | $4,420 | $110 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 54 | $4,228 | $40 |
| Examination of eye by ophthalmoscope with retinal drawing | 52 | $2,152 | $23 |
| Examination of eye by ophthalmoscope with retinal drawing | 73 | $2,064 | $17 |
| 2d ultrasound scan of eye tissue and structures | 22 | $1,668 | $45 |
| New patient visit (45+ min) | 11 | $1,547 | $141 |
| Long return visit (40+ min) | 11 | $1,453 | $132 |
| New patient complete exam of visual system | 14 | $957 | $68 |
| Examination of eye by ophthalmoscope with retinal drawing | 42 | $749 | $18 |
| Photography of the retina | 16 | $385 | $20 |
| Examination of eye by ophthalmoscope with retinal drawing | 16 | $385 | $24 |
Medicaid work
$105,159 in 2024
Medicaid paid $105,159 for 1,793 billed services this clinician did in 2024, up to 69 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Intravitreal injection of a pharmacologic agent (separate procedure) | 616 | $59,473 |
| Aflibercept injection | 46 | $25,609 |
| Return visit (30+ min) | 349 | $13,176 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 746 | $6,787 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 36 | $114 |
| 2024 | 1,793 | 5 | 69 | $105,159 |
| 2023 | 2,015 | 4 | 75 | $118,599 |
| 2022 | 1,272 | 4 | 57 | $46,308 |
| 2021 | 1,112 | 5 | 59 | $51,569 |
| 2020 | 1,172 | 3 | 57 | $48,476 |
| 2019 | 1,715 | 4 | 62 | $106,153 |
| 2018 | 1,772 | 4 | 64 | $176,299 |
See the largest Medicaid services in earlier years
2023
| Intravitreal injection of a pharmacologic agent (separate procedure) | 700 | $64,834 |
| Aflibercept injection | 67 | $36,403 |
| Return visit (30+ min) | 433 | $9,746 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 815 | $7,616 |
2022
| Intravitreal injection of a pharmacologic agent (separate procedure) | 382 | $32,883 |
| Return visit (30+ min) | 326 | $7,696 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 551 | $5,729 |
| Advance Care Planning discussed and documented advance care plan or surrogate decision maker documented in the medical record (DEM) (GER, Pall Cr) | 13 | $0 |
2021
| Intravitreal injection of a pharmacologic agent (separate procedure) | 287 | $38,625 |
| Return visit (30+ min) | 260 | $6,468 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 524 | $5,572 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 29 | $904 |
| Advance Care Planning discussed and documented advance care plan or surrogate decision maker documented in the medical record (DEM) (GER, Pall Cr) | 12 | $0 |
2020
| Intravitreal injection of a pharmacologic agent (separate procedure) | 469 | $39,766 |
| Return visit (30+ min) | 235 | $4,782 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 468 | $3,927 |
2019
| Intravitreal injection of a pharmacologic agent (separate procedure) | 622 | $61,132 |
| Aflibercept injection | 36 | $30,508 |
| Return visit (30+ min) | 330 | $7,332 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 727 | $7,181 |
2018
| Aflibercept injection | 140 | $89,633 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 624 | $70,957 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 671 | $8,161 |
| Return visit (30+ min) | 337 | $7,548 |
Drugs they prescribed that Part D paid
$8,514
Pharmacies billed $8,514 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 155) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
113 generic and 42 brand-name prescriptions · $8,514 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Azelastine | 22 | $1,829 | $34 |
| Prednisolone Acetate | 13 | $756 | $31 |
| Ketorolac Tromethamine | 11 | $476 | $20 |
Year by year
| 2024 | 155 | 55 | 0% (0) | 27% | $8,514 |
| 2023 | 167 | 58 | 0% (0) | 28% | $14,966 |
| 2022 | 222 | 72 | 0% (0) | 18% | $26,091 |
| 2021 | 221 | 77 | 0% (0) | 30% | $26,209 |
| 2020 | 166 | 61 | 0% (0) | 51% | $27,325 |
| 2019 | 122 | 53 | 0% (0) | 50% | $12,846 |
| 2018 | 111 | 36 | 0% (0) | 51% | $11,100 |
| 2017 | 155 | 52 | 0% (0) | 58% | $156,630 |
| 2016 | 144 | 54 | 0% (0) | 53% | $14,945 |
| 2015 | 117 | 50 | None | 79% | $11,766 |
| 2014 | 94 | 42 | 0% (0) | 82% | $11,250 |
| 2013 | 132 | 60 | 0% (0) | 68% | $10,799 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 5 drugs
| Azelastine | 49 | $2,093 | $43 |
| Bromfenac | 16 | $1,354 | $85 |
| Prednisolone Acetate | 22 | $967 | $44 |
| Ketorolac Tromethamine | 13 | $413 | $32 |
| Erythromycin | 15 | $201 | $13 |
2022: 6 drugs
| Xiidra | 15 | $10,077 | $672 |
| Azelastine | 94 | $3,828 | $41 |
| Valganciclovir | 13 | $2,717 | $209 |
| Prednisolone Acetate | 15 | $894 | $60 |
| Olopatadine | 12 | $584 | $49 |
| Ketorolac Tromethamine | 28 | $473 | $17 |
2021: 5 drugs
| Restasis | 16 | $12,884 | $805 |
| Azelastine | 74 | $2,902 | $39 |
| Ketorolac Tromethamine | 49 | $1,631 | $33 |
| Prednisolone Acetate | 31 | $1,615 | $52 |
| Olopatadine | 13 | $1,486 | $114 |
2020: 5 drugs
| Restasis | 21 | $17,505 | $834 |
| Prednisolone Acetate | 44 | $2,281 | $52 |
| Ketorolac Tromethamine | 32 | $1,023 | $32 |
| Azelastine | 18 | $735 | $41 |
| Latanoprost | 12 | $161 | $13 |
2019: 3 drugs
| Prednisolone Acetate | 43 | $2,000 | $47 |
| Azelastine | 14 | $546 | $39 |
| Ketorolac Tromethamine | 18 | $458 | $25 |
2018: 3 drugs
| Prednisolone Acetate | 32 | $1,417 | $44 |
| Azelastine | 15 | $637 | $42 |
| Timolol Maleate | 11 | $126 | $11 |
2017: 3 drugs
| Prednisolone Acetate | 43 | $2,530 | $59 |
| Azelastine | 34 | $1,531 | $45 |
| Latanoprost | 21 | $189 | $9 |
2016: 3 drugs
| Prednisolone Acetate | 41 | $3,404 | $83 |
| Olopatadine | 20 | $1,918 | $96 |
| Latanoprost | 14 | $175 | $12 |
2015: 3 drugs
| Prednisolone Acetate | 54 | $4,759 | $88 |
| Patanol | 12 | $2,879 | $240 |
| Eplerenone | 12 | $515 | $43 |
2014: 2 drugs
| Prednisolone Acetate | 36 | $3,121 | $87 |
| Nevanac | 12 | $2,090 | $174 |
2013: 2 drugs
| Nevanac | 17 | $2,537 | $149 |
| Prednisolone Acetate | 50 | $1,419 | $28 |
Money from drug and device companies
$42,884 in 2025
| 2025 | 14 | 35 | $40,981 | $42,884 |
| 2024 | 10 | 34 | $39,047 | $51,687 |
| 2023 | 12 | 33 | $27,524 | $29,603 |
| 2022 | 11 | 44 | $37,926 | $42,882 |
| 2021 | 8 | 16 | $35,650 | $36,067 |
| 2020 | 4 | 8 | $16,755 | $16,774 |
| 2019 | 8 | 9 | $2,128 | $2,684 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Topcon Healthcare | None | $24,529 | 15 payments
|
| Boehringer Ingelheim Pharmaceuticals | None | $5,700 | 1 payment
|
| Genentech | Cellcept | $4,200 | 1 payment
|
| Apellis Pharmaceuticals | Syfovre | $2,871 | 2 payments
|
| Boehringer Ingelheim International GmbH | None | $2,325 | 3 payments
|
| Digital Diagnostics | Lumineticscore | $1,200 | 1 payment
|
See all 34 published payments
| Topcon Healthcare | Consulting · 2025-12-08 | None | $2,000 |
| Regeneron Pharmaceuticals | Meals · 2025-12-04 | Eylea Hd | $75 |
| Topcon Healthcare | Consulting · 2025-11-10 | None | $2,000 |
| Astellas Pharma US | Meals · 2025-10-16 | Izervay | $129 |
| Topcon Healthcare | Consulting · 2025-10-14 | None | $2,000 |
| Apellis Pharmaceuticals | Consulting · 2025-10-10 | Syfovre | $2,816 |
| Topcon Healthcare | Consulting · 2025-09-15 | None | $2,000 |
| Apellis Pharmaceuticals | Meals · 2025-09-12 | None | $55 |
| Astellas Pharma US | Meals · 2025-09-11 | Izervay | $42 |
| Ocular Therapeutix | Meals · 2025-09-11 | Dextenza | $214 |
| Beaver-Visitec International | Meals · 2025-09-04 | None | $17 |
| Topcon Healthcare | Consulting · 2025-08-18 | None | $2,000 |
| Alcon Vision | Meals · 2025-08-02 | Constellation | $133 |
| Topcon Healthcare | Travel · 2025-07-21 | None | $315 |
| Topcon Healthcare | Travel · 2025-07-21 | None | $178 |
| Topcon Healthcare | Travel · 2025-07-21 | None | $35 |
| Topcon Healthcare | Consulting · 2025-07-07 | None | $2,000 |
| Regeneron Healthcare Solutions | Consulting · 2025-06-27 | Eylea Hd | $940 |
| Boehringer Ingelheim Pharmaceuticals | Consulting · 2025-06-23 | None | $5,700 |
| Astellas Pharma Global Development | Meals · 2025-06-17 | Izervay | $160 |
| Topcon Healthcare | Consulting · 2025-06-09 | None | $2,000 |
| Astellas Pharma Global Development | Meals · 2025-06-05 | Izervay | $158 |
| Topcon Healthcare | Consulting · 2025-05-12 | None | $2,000 |
| Genentech | Consulting · 2025-05-08 | Cellcept | $4,200 |
| Alcon Vision | Meals · 2025-04-14 | Constellation | $150 |
| Topcon Healthcare | Consulting · 2025-04-14 | None | $2,000 |
| Boehringer Ingelheim International GmbH | Consulting · 2025-04-07 | None | $850 |
| Topcon Healthcare | Consulting · 2025-03-10 | None | $2,000 |
| Digital Diagnostics | Consulting · 2025-03-02 | Lumineticscore | $1,200 |
| Topcon Healthcare | Consulting · 2025-02-10 | None | $2,000 |
| Genentech USA | Meals · 2025-02-07 | Vabysmo | $42 |
| Boehringer Ingelheim International GmbH | Consulting · 2025-01-13 | None | $1,275 |
| Boehringer Ingelheim International GmbH | Travel · 2025-01-13 | None | $200 |
| Topcon Healthcare | Consulting · 2025-01-13 | None | $2,000 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $51,687
| Boehringer Ingelheim International GmbH | None | $20,648 | 9 payments
|
| Topcon Healthcare | None | $15,000 | 4 payments
|
| F. Hoffmann-La Roche AG | None | $6,352 | 4 payments
|
| Regeneron Healthcare Solutions | Eylea Hd | $4,860 | 2 payments
|
| Genentech | None | $3,656 | 2 payments
|
| Genentech USA | Vabysmo | $543 | 5 payments
|
| Astellas Pharma US | Izervay | $287 | 2 payments
|
| Regeneron Pharmaceuticals | Eylea | $249 | 4 payments
|
| Astellas Pharma Global Development | Izervay | $55 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | None | $37 | 1 payment
|
2023: $29,603
| Alcon Vision | Constellation | $15,814 | 14 payments
|
| Boehringer Ingelheim International GmbH | None | $5,950 | 3 payments
|
| F. Hoffmann-La Roche AG | None | $2,944 | 1 payment
|
| Alcon Research | None | $2,100 | 3 payments
|
| Genentech | None | $1,680 | 3 payments
|
| Iridex | None | $500 | 1 payment
|
| Astellas Pharma US | None | $184 | 2 payments
|
| Regeneron Healthcare Solutions | Eylea Hd | $144 | 1 payment
|
| Biogen | None | $128 | 1 payment
|
| Genentech USA | Vabysmo | $59 | 2 payments
|
| Regeneron Pharmaceuticals | Eylea | $51 | 1 payment
|
| Ocular Therapeutix | Dextenza | $50 | 1 payment
|
2022: $42,882
| Alcon Vision | Luxor | $12,727 | 11 payments
|
| F. Hoffmann-La Roche AG | None | $11,775 | 4 payments
|
| Apellis Pharmaceuticals | None | $4,853 | 9 payments
|
| Genentech | Vabysmo | $4,575 | 5 payments
|
| Genentech USA | Vabysmo | $3,568 | 4 payments
|
| Regeneron Healthcare Solutions | Eylea | $3,272 | 5 payments
|
| EyePoint Pharmaceuticals US | Yutiq | $1,620 | 1 payment
|
| Dompe US | Oxervate | $153 | 1 payment
|
| Johnson & Johnson Surgical Vision | Tecnis Iol | $119 | 1 payment
|
| Alimera Sciences | Iluvien | $114 | 1 payment
|
| Regeneron Pharmaceuticals | Eylea | $106 | 2 payments
|
2021: $36,067
| Genentech | None | $12,450 | 6 payments
|
| Regeneron Healthcare Solutions | Eylea | $10,832 | 3 payments
|
| Boehringer Ingelheim International GmbH | None | $6,800 | 1 payment
|
| Alcon Vision | Constellation | $4,900 | 1 payment
|
| Alcon Research | Luxor | $700 | 1 payment
|
| Genentech USA | Susvimo | $190 | 2 payments
|
| Alimera Sciences | Iluvien | $119 | 1 payment
|
| Apellis Pharmaceuticals | None | $76 | 1 payment
|
2020: $16,774
| Genentech | Non-Covered Product | $7,275 | 4 payments
|
| Regeneron Healthcare Solutions | Eylea | $6,480 | 2 payments
|
| Carl Zeiss Meditec | Cirrus Hd-Oct | $3,000 | 1 payment
|
| Carl Zeiss Meditec AG | None Specified | $19 | 1 payment
|
2019: $2,684
| F. Hoffmann-La Roche AG | Lucentis | $2,128 | 1 payment
|
| Alcon Vision | Constellation | $132 | 1 payment
|
| Alimera Sciences | Iluvien | $125 | 1 payment
|
| Genentech | Lucentis | $102 | 1 payment
|
| EyePoint Pharmaceuticals US | Yutiq | $93 | 2 payments
|
| Carl Zeiss Meditec | None | $70 | 1 payment
|
| Regeneron Healthcare Solutions | Eylea | $20 | 1 payment
|
| Genentech USA | Lucentis | $15 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Astellas Pharma Global Development · A Staged Study Incorporating A Phase 1b, Multicenter, Unmasked, Dose Escalation Evaluation of Safety and Tolerability and A Phase 2, Multicenter, Unmasked, Randomized, Parallel-Group, Controlled, Proof of Concept Investigation of Efficacy and Safety of Asp7317 for Atrophy Secondary To Age-Related Macular Degeneration · 2023 | Their institution | $22,197 |
| Astellas Pharma Global Development · A Staged Study Incorporating A Phase 1b, Multicenter, Unmasked, Dose Escalation Evaluation of Safety and Tolerability and A Phase 2, Multicenter, Unmasked, Randomized, Parallel-Group, Controlled, Proof of Concept Investigation of Efficacy and Safety of Asp7317 for Atrophy Secondary To Age-Related Macular Degeneration · 2022 | Their institution | $19,590 |
| TOPCON CORPORATION · Triton Oct-A Pre-Study Pilot 2 · 2020 | Their institution | $18,075 |
| TOPCON CORPORATION · Trition Oct-A Pre-Study Pilot 1 · 2019 | Their institution | $10,498 |
| Genentech, Inc. · Va2 Phiii Yosemite · 2019 | Their institution | $10,177 |
| Regeneron Pharmaceuticals, Inc. · Eylea Clinical Development Program · 2025 | This clinician | $10,172 |
| F. Hoffmann-La Roche AG · Real-World Clinical and Anatomical Outcomes in Patients With Diabetic Macular Edema Treated With Faricimab: the Faretina-Dme Study · 2024 | This clinician | $6,028 |
| F. Hoffmann-La Roche AG · Comparison of the Relative Effectiveness of Faricimab Vs Aflibercept 8 Mg in Diabetic Macular Edema (Dme) · 2024 | This clinician | $4,448 |
| F. Hoffmann-La Roche AG · Iris: the Intelligent Retinal Imaging System · 2023 | This clinician | $4,352 |
| F. Hoffmann-La Roche AG · Real-World Clinical and Anatomical Outcomes in Patients With Neovascular Age-Related Macular Degeneration Treated With Faricimab: the Faretina-Amd Study · 2024 | This clinician | $4,216 |
| F. Hoffmann-La Roche AG · Long-Term Experience With Intravitreal Anti-Vegf in Patients With Namd Analysis of Intelligent Research in Sight Iris Registry Database · 2021 | This clinician | $3,930 |
| Genentech, Inc. · Va2 Phiii Yosemite · 2020 | Their institution | $3,584 |
| F. Hoffmann-La Roche AG · Real-World Clinical and Anatomical Outcomes in Patients With Neovascular Age-Related Macular Degeneration (Namd) Treated With Faricimab: the Faretina-Amd Study · 2024 | This clinician | $3,347 |
| F. Hoffmann-La Roche AG · How Intravitreal Anti-Vascular Endothelial Growth Factor Initial Dosing Impacts Patient Outcomes in Diabetic Macular Edema · 2024 | This clinician | $3,135 |
| F. Hoffmann-La Roche AG · How Intravitreal Anti-Vascular Endothelial Growth Factor Loading Doses Impact Patient Outcomes in Diabetic Macular Edema · 2023 | This clinician | $2,805 |
| F. Hoffmann-La Roche AG · Early Treatment Patterns and Outcomes in Patients With Diabetic Macular Edema Treated With Faricimab: the Faretina-Dme Study · 2023 | This clinician | $2,104 |
| F. Hoffmann-La Roche AG · Early Treatment Patterns and Outcomes in Patients With Neovascular Age-Related Macular Degeneration Initiating Faricimab: the Faretina-Amd Study · 2023 | This clinician | $2,104 |
| F. Hoffmann-La Roche AG · Two-Year Real-World Clinical Outcomes in Patients With Diabetic Macular Edema Treated With Faricimab in the US: the Faretina-Dme Study · 2025 | This clinician | $1,864 |
| F. Hoffmann-La Roche AG · Comparative Efficacy of Faricimab for the Treatment of Diabetic Macular Edema: A Systematic Literature Review and Network Meta-Analysis · 2024 | This clinician | $1,566 |
| F. Hoffmann-La Roche AG · 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Neovascular Age-Related Macular Degeneration: Faretina-Amd · 2025 | This clinician | $1,556 |
| F. Hoffmann-La Roche AG · 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema: the Faretina-Dme Study · 2025 | This clinician | $1,556 |
| F. Hoffmann-La Roche AG · Real-World Effectiveness of Faricimab in Patients With Diabetic Macular Edema: 12-Month Outcomes From Faretina-Dme and Farwide-Dme Studies · 2024 | This clinician | $1,417 |
| F. Hoffmann-La Roche AG · Real-World Effectiveness of Faricimab in Patients With Neovascular Age-Related Macular Degeneration: 12-Month Outcomes From Faretina-Namd and Farwide-Namd Studies · 2024 | This clinician | $1,417 |
| F. Hoffmann-La Roche AG · 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Neovascular Age-Related Macular Degeneration: Faretina-Amd · 2024 | This clinician | $1,416 |
| F. Hoffmann-La Roche AG · Real-World Clinical Outcomes Update in Patients With Diabetic Macular Edema Treated With Faricimab in the US: the Faretina-Dme Study · 2025 | This clinician | $1,370 |
| F. Hoffmann-La Roche AG · Real-World Clinical Outcomes Update in Patients With Neovascular Age-Related Macular Degeneration in the US: the Faretina-Amd Study · 2025 | This clinician | $1,370 |
| Astellas Pharma Global Development · A Phase 1b, Multicenter, Dose Escalation, Evaluation of Safety and Tolerability of Asp7317 for Geographic Atrophy Secondary To Age-Related Macular Degeneration · 2022 | Their institution | $1,244 |
| F. Hoffmann-La Roche AG · 2-Year Real-World Clinical and Anatomical Outcomes in Patients With Neovascular Age-Related Macular Degeneration (Namd) and Diabetic Macular Edema (Dme) Treated With Faricimab in the United States: the Faretina Study · 2025 | This clinician | $1,206 |
| F. Hoffmann-La Roche AG · Two-Year Real-World Clinical Outcomes in Patients With Neovascular Age-Related Macular Degeneration Treated With Faricimab in the US: the Faretina-Namd Study · 2025 | This clinician | $1,200 |
| F. Hoffmann-La Roche AG · 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema: the Faretina-Dme Study · 2024 | This clinician | $1,117 |
| F. Hoffmann-La Roche AG · Uk Faricimab Real-World Evidence (Uk Farwide) Study: Evaluation of Faricimab Uptake Patient Characteristics Treatment Patterns and Visual Acuity Outcomes Over Time · 2024 | This clinician | $1,113 |
| F. Hoffmann-La Roche AG · Early Treatment Patterns and Outcomes in Diabetic Macular Edema Patients Initiating Faricimab in the US and Uk · 2023 | This clinician | $1,096 |
| F. Hoffmann-La Roche AG · Faretina-Dme-Six-Month Treatment Patterns and Outcomes in Patients With Diabetic Macular Edema Treated With Faricimab: An Iris (Tm) Registry Analysis · 2023 | This clinician | $1,096 |
| F. Hoffmann-La Roche AG · Early Treatment Patterns and Outcomes in Neovascular Age-Related Macular Degeneration (Namd) Patients Initiating Faricimab in the US and Uk · 2023 | This clinician | $1,096 |
| F. Hoffmann-La Roche AG · Iris Namd Treatment Patterns Study · 2021 | This clinician | $509 |
| F. Hoffmann-La Roche AG · Comparative Efficacy of Faricimab for the Treatment of Diabetic Macular Edema: A Systematic Literature Review and Network Meta-Analysis · 2023 | This clinician | $481 |
| F. Hoffmann-La Roche AG · Real-World Clinical and Anatomical Outcomes in Patients With Diabetic Macular Edema Treated With Faricimab: the Faretina-Dme Study · 2023 | This clinician | $480 |
| F. Hoffmann-La Roche AG · Real-World Clinical and Anatomical Outcomes in Patients With Neovascular Age-Related Macular Degeneration Treated With Faricimab: the Faretina-Amd Study · 2023 | This clinician | $480 |
| F. Hoffmann-La Roche AG · Real-World Clinical and Anatomical Outcomes in Patients With Diabetic Macular Edema (Dme) and Neovascular Age-Related Macular Degeneration (Namd) Treated With Faricimab in the United States: the Faretina Study · 2024 | This clinician | $426 |
| F. Hoffmann-La Roche AG · Two-Year Real-World Clinical Outcomes Update With Faricimab in Patients With Neovascular Age-Related Macular Degeneration in the USA: the Faretina-Amd Study · 2024 | This clinician | $421 |
| F. Hoffmann-La Roche AG · 12-Month Real-World Clinical Outcomes in Patients With Diabetic Macular Edema Treated With Faricimab in the USA: the Faretina-Dme Study · 2024 | This clinician | $421 |
| F. Hoffmann-La Roche AG · Faretina-Dme Real-World Injection Frequency, Visual Acuity and Anatomical Outcomes ?12-Month Follow Up · 2023 | This clinician | $359 |
| F. Hoffmann-La Roche AG · Indirect Comparison of the Relative Effectiveness of Faricimab Vs Aflibercept 8 Mg in Dme and Namd · 2025 | This clinician | $306 |
| F. Hoffmann-La Roche AG · 2-Year Real-World Clinical and Anatomical Outcomes in Patients With Neovascular Age-Related Macular Degeneration (Namd) and Diabetic Macular Edema (Dme) Treated With Faricimab in the United States: the Faretina Study · 2024 | This clinician | $296 |
Professional record
- NPI
- 1144438987
- Licence
- CA A106892California A106892: Current · expires 2027-03-31
- Trained
- Stanford University School of Medicine, 2005
- Group
- Stanford Health Care · University Healthcare Alliance · County of Santa Clara
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207WX0107X (207WX0107X); Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 2452 Watson Ct, Palo Alto, CA, 94303
- NPI first listed
- 2007-05-17
- NPI last updated
- 2024-03-21
- NPI record certified
- 2024-03-21
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 2452 Watson Ct, Palo Alto, CA, 94303